Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds

References

• Hassan AHE, Choi E, Yoon YM, et al. Natural products hybrids: 3,5,4'-trimethoxystilbene-5,6,7-trimethoxyflavone chimeric analogs as potential cytotoxic agents against diverse human cancer cells. Eur J Med Chem 2019;161:559–80.
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Park HR, Yoon YM, et al. Antiproliferative 3-deoxysphingomyelin analogs: design, synthesis, biological evaluation and molecular docking of pyrrolidine-based 3-deoxysphingomyelin analogs as anticancer agents. Bioorg Chem 2019;84:444–55.
   PubMed Web of Science ®Google Scholar
• Alam MM, Hassan AHE, Lee KW, et al. Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. Bioorg Chem 2019;84:51–62.
   PubMed Web of Science ®Google Scholar
• Alam MM, Hassan AHE, Kwon YH, et al. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents. Arch Pharm Res 2018;41:35–45.
   PubMed Web of Science ®Google Scholar
• Kumar S, Deep A, Narasimhan B. A review on synthesis, anticancer and antiviral potentials of pyrimidine derivatives. Curr Bioact Compd 2019;15:289–303.
   Google Scholar
• Kaur R, Kaur P, Sharma S, et al. Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature. Recent Pat Anticancer Drug Discov 2014;10:23–71.
   Web of Science ®Google Scholar
• Elkamhawy A, Hassan AHE, Paik S, et al. EGFR inhibitors from cancer to inflammation: discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor. Bioorg Chem 2019;86:112–8.
   PubMed Web of Science ®Google Scholar
• Farag AK, Elkamhawy A, Londhe AM, et al. Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders. Eur J Med Chem 2017;141:657–75.
   PubMed Web of Science ®Google Scholar
• Kumar S, Narasimhan B. Therapeutic potential of heterocyclic pyrimidine scaffolds. Chem Cent J 2018;12:38.
   PubMedGoogle Scholar
• Lee JY, Park JH, Lee SJ, et al. Styrylquinazoline derivatives as HIV-1 integrase inhibitors. Arch Pharm 2002;335:277–82.
   PubMed Web of Science ®Google Scholar
• Lee JY, Park YK, Seo SH, et al. 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase. Arch Pharm 2001;334:357–60.
   PubMed Web of Science ®Google Scholar
• Lee YS, Seo SH, Yang BS, Lee JY. Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors. Arch Pharm 2005;338:502–5.
   PubMed Web of Science ®Google Scholar
• Lee JY, Park YK, Seo SH, et al. [1,4]dioxano[2,3-g]quinazolines as inhibitors of epidermal growth factor receptor kinase. Arch Pharm 2002;335:487–94.
   PubMed Web of Science ®Google Scholar
• Elkamhawy A, Paik S, Hassan AHE, et al. Hit discovery of 4-amino-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide: a novel EGFR inhibitor from a designed small library. Bioorg Chem 2017;75:393–405.
   PubMed Web of Science ®Google Scholar
• Romu AA, Lei Z, Zhou B, et al. Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors. Bioorg Med Chem Lett 2017;27:4832–7.
   PubMed Web of Science ®Google Scholar
• Farag AK, Hassan AHE, Jeong H, et al. First-in-class DAPK1/CSF1R dual inhibitors: discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidi n-5-yl)benzamide as a potential anti-tauopathies agent. Eur J Med Chem 2019;162:161–75.,
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Yoo SY, Lee KW, et al. Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: discovery of novel p38-alpha MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. Eur J Med Chem 2019;180:253–67.
   PubMed Web of Science ®Google Scholar
• Kang S, Lee JM, Jeon B, et al. Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. Eur J Med Chem 2018;151:186–98.
   PubMed Web of Science ®Google Scholar
• Allison M. NCATS launches drug repurposing program. Nat Biotechnol 2012;30:571–2.
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673–83.
   PubMed Web of Science ®Google Scholar
• Farag AK, Roh EJ. Death‐associated protein kinase (DAPK) family modulators: current and future therapeutic outcomes. Med Res Rev 2019;39:349–85.
   PubMed Web of Science ®Google Scholar
• Elbadawy M, Usui T, Yamawaki H, Sasaki K. Novel functions of death-associated protein kinases through mitogen-activated protein kinase-related signals. Int J Mol Sci 2018;19:3031.
   Web of Science ®Google Scholar
• Huang Y, Chen L, Guo L, et al. Evaluating DAPK as a therapeutic target. Apoptosis 2014;19:371–86.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao D, Poage GM, et al. Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest 2015;125:2707–20.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Bai T, Yukawa K. Death-associated protein kinase is essential for the survival of various types of uterine cancer cells. Int J Oncol 2010;37:1017–22.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Bai T, Yukawa K. Specific downregulation of death-associated protein kinase enhances Fas-mediated apoptosis in the human differentiated endometrial adenocarcinoma cell line, HHUA. Eur J Gynaecol Oncol 2011;32:293–6.
   PubMed Web of Science ®Google Scholar
• Shani G, Marash L, Gozuacik D, et al. Death-associated protein kinase phosphorylates ZIP kinase, forming a unique kinase hierarchy to activate its cell death functions. Mol Cell Biol 2004;24:8611–26.
   PubMed Web of Science ®Google Scholar
• Leister P, Felten A, Chasan AI, Scheidtmann KH. ZIP kinase plays a crucial role in androgen receptor-mediated transcription. Oncogene 2008;27:3292–300.
   PubMed Web of Science ®Google Scholar
• Togi S, Ikeda O, Kamitani S, et al. Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta-catenin signaling through interaction with Nemo-like kinase and T-cell factor 4 (NLK/TCF4). J Biol Chem 2011;286:19170–7.
   PubMed Web of Science ®Google Scholar
• Kake S, Usui T, Ohama T, et al. Death-associated protein kinase 3 controls the tumor progression of A549 cells through ERK MAPK/c-Myc signaling. Oncol Rep 2017;37:1100–6.
   PubMed Web of Science ®Google Scholar
• Kacinski BM. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 1997;46:71–4.
   PubMed Web of Science ®Google Scholar
• Tang R, Beuvon F, Ojeda M, et al. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J Cell Biochem 1992;50:350–6.
   PubMed Web of Science ®Google Scholar
• Kirma N, Hammes LS, Liu YG, et al. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. Cancer Res 2007;67:1918–26.
   PubMed Web of Science ®Google Scholar
• Skrzypski M, Dziadziuszko R, Jassem E, et al. Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes. Clin Lung Cancer 2013;14:666–73.e2.
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Walter K, Kreher S, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 2010;16:571–9.
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846–59.
   PubMed Web of Science ®Google Scholar
• Pradel LP, Ooi CH, Romagnoli S, et al. Macrophage susceptibility to emactuzumab (RG7155) treatment. Mol Cancer Ther 2016;15:3077–86.
   PubMed Web of Science ®Google Scholar
• Gomez-Roca CA, Cassier PA, Italiano A, et al. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors. J Clin Oncol 2015;33:3005.
   Google Scholar
• Baghdadi M, Endo H, Takano A, et al. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Sci Rep 2018;8:418.
   PubMed Web of Science ®Google Scholar
• Yuan X, Zhang J, Li D, et al. Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis. Gynecol Oncol 2017;147:181–187.
   PubMed Web of Science ®Google Scholar
• Zhao XX, Qu JK, Sun YC, et al. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget 2017;8:30576–30586.,
   PubMedGoogle Scholar
• Kubler K, Ayub TH, Weber SK, et al. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol 2014;135:176–183.
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012;7:e50946.
   PubMed Web of Science ®Google Scholar
• Anastassiadis T, Deacon SW, Devarajan K, et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1039–1045.
   PubMed Web of Science ®Google Scholar
• Kinase Assay Protocol. Available from: http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx [last accessed 16 Oct 2019]
   Google Scholar
• NCI-60 Screening Methodology. Available from: https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm [last accessed 16 Oct 2019].
   Google Scholar
• Abel R, Young T, Farid R, et al. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. J Am Chem Soc 2008;130:2817–2831.
   PubMed Web of Science ®Google Scholar
• Bissantz C, Kuhn B, Stahl M. A medicinal chemist’s guide to molecular interactions. J Med Chem 2010;53:5061–5084.
   PubMed Web of Science ®Google Scholar
• Elkamhawy A, Park JE, Hassan AHE, et al. Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: a new modulator for amyloid beta-induced mitochondrial dysfunction. Eur J Med Chem 2017;128:56–69.
   PubMed Web of Science ®Google Scholar